Abidemi Adeniji, PhD

Biostatistics & Data Sciences, Boehringer Ingelheim Pharmaceuticals, Ridgefield, Connecticut

JCP
BI 1358894 in Borderline Personality Disorder
Original Research

January 13, 2025

Although the primary endpoint was not met, BI 1358894 was well-tolerated with no increase in self-harm or suicidality.
, , , et al

Celebrating
85 Years

Read the Journal of Clinical Psychiatry

Subscribe to read
more articles

Subscribe